Lytix Biopharma (LYTIX) Q2 2024 earnings summary

Executive summary

• Achieved strong clinical progress with LTX-315, including 86% tumor reduction and 51% complete clearance in BCC, and 40% disease control with durable responses up to 17 months in late-stage melanoma.

• Three ongoing or planned phase II studies in BCC and melanoma, with a new neoadjuvant study (NeoLIPA) in early-stage melanoma set to start in Q3/H2 2024.

• Developed a new LTX-401 formulation with superior preclinical efficacy, extended patent protection, and targeting deep-seated cancers.

• Licensing agreement with Verrica Pharmaceuticals for BCC, with potential for up to $110 million in milestones and 10-15% royalties.

• Positive market response to BCC data, with Verrica's share price rising 30% after announcement.

Financial highlights

• H1 2024 revenue was NOK 10.5 million, up from NOK 74 thousand in H1 2023, mainly from LTX-315 sales to Verrica.

• Operating expenses for Q2 2024 were NOK 21.5 million, down from NOK 24.4 million in Q2 2023; H1 2024 operating expenses were NOK 50.8 million, down from NOK 58.7 million in H1 2023.

• Loss for H1 2024 was NOK 39.6 million, improved from NOK 51.1 million in H1 2023.

• Cash and short-term investments at June 30, 2024, were NOK 60.2 million, up from NOK 27.4 million at year-end 2023.

• NOK 50 million raised in April 2024 via share offering, primarily from existing shareholders, extending cash runway into 2025.

Outlook and guidance

• Cash runway secured into 2025, enabling completion of key milestones and clinical studies.

• NeoLIPA phase II study in early-stage melanoma to start in Q3/H2 2024, with interim results expected in 2025.

• Final results from Verrica's BCC study expected in Q3/Q4 2024, immunological analysis in Q1 2025, and FDA end-of-phase-2 meeting in H1 2025.

• ATLAS-IT-05 study finalization expected in H2 2025.

• Preparing LTX-401 for clinical Phase I with new formulation and regulatory meeting in Q1 2025.